Targeting death-receptors in radiation therapy.
作者： Olivier Niemöller , Claus Belka
DOI: 10.1007/400_2009_17
关键词:
摘要: The development of apoptosis resistance is a crucial step during the pathogenesis malignant tumors. Thus, any treatment approach overcoming may be valuable tool in oncology. Although variety treatments induce apoptosis, only very few specifically trigger programmed cell death. In this regard, class inducing ligands turn out to have considerable potential TNF-α-related apoptosis-inducing ligand (TRAIL/Apo2L) most promising candidate, either alone or combination with established cancer therapies, since it induces wide range cells while sparing normal tissues.
springer.com
sci-hub.se 参考文章(91)
Gen Sheng Wu, Timothy F. Burns, E. Robert McDonald, Wen Jiang, Ray Meng, Ian D. Krantz, Gary Kao, Dai-Di Gan, Jun-Ying Zhou, Ruth Muschel, Stanley R. Hamilton, Nancy B. Spinner, Sanford Markowitz, Gary Wu, Wafik S. El-Deiry, KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene Nature Genetics. ,vol. 17, pp. 141- 143 ,(1997) , 10.1038/NG1097-141
P Marini, S Denzinger, D Schiller, S Kauder, S Welz, R Humphreys, P T Daniel, V Jendrossek, W Budach, C Belka, Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo Oncogene. ,vol. 25, pp. 5145- 5154 ,(2006) , 10.1038/SJ.ONC.1209516
Justine Rudner, Verena Jendrossek, Kirsten Lauber, Peter T Daniel, Sebastian Wesselborg, Claus Belka, Type I and type II reactions in TRAIL-induced apoptosis -- results from dose-response studies. Oncogene. ,vol. 24, pp. 130- 140 ,(2005) , 10.1038/SJ.ONC.1208191
Guohua Pan, Jian Ni, Ying-Fei Wei, Guo-liang Yu, Reiner Gentz, Vishva M Dixit, None, An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL Science. ,vol. 277, pp. 815- 818 ,(1997) , 10.1126/SCIENCE.277.5327.815
S.A. Marsters, J.P. Sheridan, R.M. Pitti, A. Huang, M. Skubatch, D. Baldwin, J. Yuan, A. Gurney, A.D. Goddard, P. Godowski, A. Ashkenazi, A novel receptor for Apo2L/TRAIL contains a truncated death domain Current Biology. ,vol. 7, pp. 1003- 1006 ,(1997) , 10.1016/S0960-9822(06)00422-2
Guohua Pan, Karen O'Rourke, Arul M Chinnaiyan, Reiner Gentz, Reinhard Ebner, Jian Ni, Vishva M Dixit, None, The Receptor for the Cytotoxic Ligand TRAIL Science. ,vol. 276, pp. 111- 113 ,(1997) , 10.1126/SCIENCE.276.5309.111
Clarissa von Haefen, Bernhard Gillissen, Philipp G Hemmati, Jana Wendt, Dilek Güner, Alicja Mrozek, Claus Belka, Bernd Dörken, Peter T Daniel, Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway Oncogene. ,vol. 23, pp. 8320- 8332 ,(2004) , 10.1038/SJ.ONC.1207971
David H. Lynch, Marek Z. Kubin, Thomas S. Griffith, Wilson A. Chin, Glenn C. Jackson, Intracellular Regulation of TRAIL-Induced Apoptosis in Human Melanoma Cells Journal of Immunology. ,vol. 161, pp. 2833- 2840 ,(1998)
Xufeng Chen, Rakesh K. Srivastava, Karthikeyan Kandasamy, Differential Roles of RelA (p65) and c-Rel Subunits of Nuclear Factor κB in Tumor Necrosis Factor-related Apoptosis-inducing Ligand Signaling Cancer Research. ,vol. 63, pp. 1059- 1066 ,(2003)
Kimihisa Ichikawa, Weimin Liu, Limin Zhao, Zheng Wang, Di Liu, Toshiaki Ohtsuka, Huangge Zhang, John D. Mountz, William J. Koopman, Robert P. Kimberly, Tong Zhou, Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity Nature Medicine. ,vol. 7, pp. 954- 960 ,(2001) , 10.1038/91000